Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB)

Metformin plus a dipeptidyl peptidase‐4 inhibitor (DPP‐4i) is the most common therapy for Japanese patients with type 2 diabetes. This 24‐week, multicentre, open‐label, parallel‐group trial randomized patients on dual therapy to add‐on tofogliflozin (20 mg/day, n = 33) or glimepiride (0.5 mg/day, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitazawa, Toru, Seino, Hiroaki, Ohashi, Hiroshi, Inazawa, Takeshi, Inoue, Masahiro, Ai, Masumi, Fujishiro, Midori, Kuroda, Hisamoto, Yamada, Masayo, Anai, Motonobu, Ishihara, Hisamitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496555/
https://www.ncbi.nlm.nih.gov/pubmed/32314464
http://dx.doi.org/10.1111/dom.14059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496555/
https://www.ncbi.nlm.nih.gov/pubmed/32314464
http://dx.doi.org/10.1111/dom.14059

Ejemplares similares